UNSPSC 51383504: Ketorolac

This classification denotes a cyclooxygenase inhibitor with the molecular formula C15H13NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YZI5105V0L, chemically known as 5-benzoyl-2,3-dihydro-1h-pyrrolizine-1-carboxylic acid but generally known as ketorolac, which bears US NIH Compound Identifier 3826. European Medicines Agency schedules Ketorolac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08376MIG.

UNSPSC 51383504 Ketorolac is a Commodity code that captures individual pharmaceutical products procured by state and local health agencies, though recent opportunities tagged under this code show substantial scope divergence. Seminole County, Florida is soliciting naloxone and safe drug deactivation systems; the Texas Health and Human Services Commission issued an RFI on direct-to-manufacturer prescription delivery models; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is seeking generic multi-source pharmaceuticals and OTC products through an RFP. The actual buying under this code spans emergency response medications (naloxone), generic pharmaceutical ingredients and finished goods for state and local distribution networks, and over-the-counter remedies—often procured through state purchasing coalitions and cooperative vehicles rather than single jurisdictions. Issuing bodies include state health departments, county health boards, and regional multi-state cooperative purchasing organizations; MMCAP's involvement signals that cooperative purchasing agreements are a primary channel for volume-based pharmaceutical procurement across participating state and local facilities.

Geographic activity centers on the Midwest and South, with recent solicitations in Minnesota (MMCAP, representing multiple states including Oregon), Texas (HHS Commission), and Florida (Seminole County). MMCAP's RFP for generic multi-source pharmaceuticals closed March 26, 2026, with evaluations weighted heavily on price competitiveness (75 percent) and required vendor compliance with cGMP, FDA requirements, and Drug Supply Chain Security Act certification; winners must maintain relationships with authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, with a contract term of two years effective July 1, 2026. Seminole County's IFB for naloxone and drug deactivation systems (1,900 units and 800 systems annually, respectively) closed July 26, 2023, with quarterly deliveries to its Community Health Building in Sanford and potentially FEMA-backed funding. The Texas HHS Commission's RFI, posted April 3, 2026, gathered preliminary vendor capabilities on direct-to-manufacturer prescription fulfillment models outside traditional PBM and GPO channels to inform a future formal procurement.